BriTROC1: Sample collection study to investigate the role of Homologous Recombination Deficiency in platinum sensitivity in recurrent high grade serous ovarian cancer

HS Greater Glasgow & Clyde (UK)0 个研究点目标入组 300 人开始时间: 2013年8月27日最近更新: 2023年11月6日

适应症

试验速览

2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37474499/ Acquisition of resistance (added 20/10/2023) 2019 Results article in https://pubmed.ncbi.nlm.nih.gov/30862952/ Safety and utility of image-guided research biopsies (added 24/10/2023)

•1. Patients with recurrent histologically-proven high grade serous ovarian cancer, primary peritoneal carcinoma or fallopian tube cancer.
•2. Patients may have received no more than two lines of prior chemotherapy
•3. Availability of formalin-fixed, paraffin-embedded tissue taken at the time of original diagnosis of high grade serous ovarian cancer. This may be primary surgical debulking specimen OR core biopsy. For those with only a core biopsy from time of diagnosis, availability of specimen taken at interval debulking surgery is desirable, but not essential.
•4. Patients must have disease deemed suitable for imaging-guided biopsy (ultrasound or CT) by an experienced radiologist.
•5. Target Gender: Female, age = 18 years
•6. Written informed consent.
•7. Able to apply with study procedures.
•8. Life expectancy > 3 months
•9. No contraindication to biopsy as appropriate

•1. Ovarian, primary peritoneal or fallopian tube cancer of non-high grade serous pathology i.e. low grade serous, clear cell and endometrioid as well as carcinosarcoma/Malignant Mixed Mullerian Tumor (MMMT)
•2. Borderline/low malignant potential tumours
•3. Any non-epithelial ovarian malignancy
•4. Patients with asymptomatic rising CA125 with no radiological evidence of recurrent ovarian cancer.
•5. Original diagnosis of high grade serous cancer made on cytology only

发起方

HS Greater Glasgow & Clyde (UK)